Department of Anesthesiology, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, China (mainland).
Department of General Surgery, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, China (mainland).
Med Sci Monit. 2017 Oct 19;23:4989-4994. doi: 10.12659/msm.902652.
BACKGROUND Etomidate and rocuronium are often paired in rapid-sequence anesthesia induction. However, the effect of pretreatment with oxycodone on myoclonic and withdrawal movements has not been previously investigated. The aim of this study was to evaluate the effects of oxycodone on the incidence and severity of etomidate-induced myoclonus and rocuronium-induced nociceptive withdrawal movements during rapid-sequence anesthesia induction. MATERIAL AND METHODS We randomly divided 120 patients into the saline group (group S) and the oxycodone group (group O) (n=60 in each group). Patients received 0.05 mg/kg oxycodone or saline intravenously 2 min before administration of 0.3 mg/kg etomidate. The occurrence and severity of myoclonus were assessed after administration of etomidate, then rocuronium was injected, followed by evaluation of withdrawal movements. RESULTS The total frequency of involuntary movements following sequential administration of etomidate and rocuronium was significantly lower in Group O than in Group S (28.3% vs. 90%, p<0.001). The total frequency and grade 3 severity of myoclonus following etomidate injection in Group O was significantly lower than in Group S (25.0% vs. 63.3% for total frequency; 0 vs. 10 for grade 3 severity, P<0.001). The total frequency and grade 3 intensity of withdrawal movements were significantly less in Group O than in Group S (6.7% vs. 73.3% for total frequency; 0 vs. 11 for grade 3 intensity, P<0.001). CONCLUSIONS Oxycodone is effective for simultaneously preventing etomidate-induced myoclonus and rocuronium-induced withdrawal movements during general anesthesia induction.
依托咪酯和罗库溴铵常联合用于快速序贯麻醉诱导。然而,之前尚未研究过羟考酮预处理对肌阵挛和撤药运动的影响。本研究旨在评估羟考酮对快速序贯麻醉诱导中依托咪酯诱导肌阵挛和罗库溴铵诱导疼痛性撤药运动的发生率和严重程度的影响。
我们将 120 名患者随机分为生理盐水组(S 组)和羟考酮组(O 组)(每组 60 例)。患者在给予 0.3mg/kg 依托咪酯前 2 分钟分别静脉注射 0.05mg/kg 羟考酮或生理盐水。在给予依托咪酯后评估肌阵挛的发生和严重程度,然后给予罗库溴铵,并评估撤药运动。
O 组序贯给予依托咪酯和罗库溴铵后,不自主运动的总频率明显低于 S 组(28.3%比 90%,p<0.001)。O 组依托咪酯注射后肌阵挛的总频率和 3 级严重程度明显低于 S 组(总频率:25.0%比 63.3%;3 级严重程度:0 比 10,p<0.001)。O 组撤药运动的总频率和 3 级强度明显低于 S 组(总频率:6.7%比 73.3%;3 级强度:0 比 11,p<0.001)。
羟考酮可有效预防全身麻醉诱导中依托咪酯诱导的肌阵挛和罗库溴铵诱导的撤药运动。